Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.48 |
| ▸ | MDK | P21741 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.42 |
| ▸ | CD69 | Q07108 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21189935 | 1.00 | MAPK1 (0.53) | MAPK1LGALS3MDKMEN1KMT2A | |
| SCHEMBL26187782 | 0.95 | MAPK1 (0.53) | MAPK1LGALS3MDKMEN1KMT2A | |
| SCHEMBL26261755 | 0.94 | MAPK1 (0.50) | MAPK1LGALS3MDKMEN1KMT2A | |
| SCHEMBL23322820 | 0.94 | MAPK1 (0.51) | MAPK1LGALS3MDKMEN1KMT2A | |
| SCHEMBL15867554 | 0.93 | MAPK1 (0.49) | MAPK1LGALS3MDKMEN1KMT2A | |
| SCHEMBL16298993 | 0.93 | MDK (0.48) | MAPK1LGALS3MDKMEN1KMT2A | |
| SCHEMBL16359449 | 0.93 | MAPK1 (0.52) | MAPK1LGALS3MDKMEN1KMT2A | |
| SCHEMBL26953373 | 0.92 | MAPK1 (0.49) | MAPK1LGALS3MDKMEN1KMT2A | |
| SCHEMBL16358004 | 0.92 | MAPK1 (0.51) | MAPK1LGALS3MDKMEN1KMT2A | |
| SCHEMBL15102708 | 0.92 | MAPK1 (0.46) | MAPK1LGALS3MDKMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240182-A1 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-07-18 | — | — | US | disclosed |
| US-20240209372-A1 | PROLINE DEHYDROGENASE 2 (PRODH2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-06-27 | — | — | US | disclosed |
| US-12018260-B2 | Tunable Reversir™ compounds | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-02-29 | — | — | US | disclosed |
| US-11840692-B2 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230365965-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | GENZYME CORPORATION (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230323357-A1 | TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230323363-A1 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-10-12 | — | — | US | disclosed |
| US-20230310485-A1 | POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2012177949-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF PROTEIN C (PROC) GENES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177947-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) GENES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012178033-A2 | SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177784-A2 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSTIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012135246-A2 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-8106022-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| WO-2011127180-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011091396-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MYLIP/IDOL GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20100179309-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2010-07-15 | — | — | US | disclosed |
| WO-2009073809-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310485-A1 | POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF | AGT, AGTR1, AGTR2 | MAPK1 1168/4885LGALS3 1978/4885MDK 1762/4885 |
| US-20230323357-A1 | TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | TRAF6, TRAF2, TNFRSF1A | MAPK1 3898/4885LGALS3 2621/4885MDK 3403/4885 |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | DPP4, DPP3, DPP7 | MAPK1 4702/4885LGALS3 550/4885MDK 2341/4885 |
| US-12018260-B2 | Tunable Reversir™ compounds | SNRPE, PLK1, LDLR | MAPK1 3310/4885LGALS3 3128/4885MDK 3304/4885 |
| US-20100179309-A1 | MODIFIED iRNA AGENTS | HNRNPA0, HNRNPA1, SNRPA | MAPK1 4435/4885LGALS3 481/4885MDK 3679/4885 |
| US-20230323363-A1 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | KHK, HNRNPK, HK1 | MAPK1 3446/4885LGALS3 3174/4885MDK 645/4885 |
| US-20230365965-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | SERPINC1, SERPINH1, SERPINE1 | MAPK1 4054/4885LGALS3 1401/4885MDK 2632/4885 |
| US-11840692-B2 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | TEK, RNASE1, LDLR | MAPK1 4697/4885LGALS3 443/4885MDK 1230/4885 |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALK, DGKG, EIF2AK2 | MAPK1 2634/4885LGALS3 1382/4885MDK 2312/4885 |
| US-20240209372-A1 | PROLINE DEHYDROGENASE 2 (PRODH2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | RNASEH1, IMPDH2, RNASEL | MAPK1 4640/4885LGALS3 4298/4885MDK 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.